Published in N Engl J Med on September 23, 2010
Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. Thromb Res (2015) 0.82
The state of the art of endothermal ablation. Lasers Med Sci (2014) 0.77
Inhibitors of propagation of coagulation: factors V and X. Br J Clin Pharmacol (2011) 0.76
A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. J Thromb Haemost (2012) 0.76
Endovenous saphenous vein ablation in patients with acute isolated superficial-vein thrombosis. Phlebology (2013) 0.75
Superficial venous thrombosis: disease progression and evolving treatment approaches. Vasc Health Risk Manag (2011) 0.75
Thrombosis: An effective therapy for leg SVT. Nat Rev Cardiol (2010) 0.75
ACP Journal Club. Fondaparinux reduced a composite of VTE complications or death in superficial leg-vein thrombosis. Ann Intern Med (2011) 0.75
Initial management and outcomes after superficial thrombophlebitis: The Cardiovascular Research Network Venous Thromboembolism study. J Hosp Med (2016) 0.75
[Not Available]. Praxis (Bern 1994) (2011) 0.75
Higher order response adaptive urn designs for clinical trials with highly successful treatments. J R Stat Soc Ser C Appl Stat (2015) 0.75
Treatment of superficial thrombophlebitis. N Engl J Med (2011) 0.75
Treatment of superficial thrombophlebitis. N Engl J Med (2011) 0.75
Superficial phlebitis and phase 3.5 trials. N Engl J Med (2010) 0.75
Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study. Expert Opin Pharmacother (2011) 0.75
[Diagnostic workup and therapy of acute venous diseases]. Hautarzt (2017) 0.75
Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet (2002) 8.09
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med (2010) 5.06
Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation (2003) 4.25
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet (2007) 3.66
Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med (2010) 3.64
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med (2008) 2.85
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis (2013) 2.71
Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol (2007) 2.63
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med (2004) 2.34
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31
Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med (2003) 2.28
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology (2006) 2.18
Direct thrombin inhibitors. N Engl J Med (2005) 2.15
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer (2013) 2.14
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev (2012) 2.09
An update on the management of hematologic malignancies in pregnancy. Womens Health (Lond Engl) (2014) 2.05
Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation (2008) 2.00
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost (2008) 1.91
A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J (2004) 1.80
The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation (2014) 1.64
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med (2005) 1.64
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med (2007) 1.63
Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood (2011) 1.63
Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis (2009) 1.63
Early migration of tibial components is associated with late revision: a systematic review and meta-analysis of 21,000 knee arthroplasties. Acta Orthop (2012) 1.62
Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost (2006) 1.57
Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost (2012) 1.57
QT dynamicity and sudden death after myocardial infarction: results of a long-term follow-up study. J Cardiovasc Electrophysiol (2003) 1.56
Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension (2013) 1.52
Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation (2010) 1.50
Compliance-guided therapy : a new insight into the potential role of clinical pharmacologists. Clin Pharmacokinet (2006) 1.50
Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost (2008) 1.48
A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med (2013) 1.42
Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women. Thromb Res (2008) 1.41
A randomized double-blind trial of upward progressive versus degressive compressive stockings in patients with moderate to severe chronic venous insufficiency. J Vasc Surg (2012) 1.40
Functional hypoparathyroidism in postmenopausal women with fragility fracture. Joint Bone Spine (2011) 1.39
Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study. Blood (2013) 1.39
[Thromboprophylaxis with low-molecular-weight heparin insufficient in high-risk pregnancy]. Ned Tijdschr Geneeskd (2011) 1.38
Use of the Delphi method to facilitate antithrombotics prescription during pregnancy. Thromb Res (2010) 1.38
Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest (2007) 1.38
Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol (2012) 1.33
Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol (2008) 1.29
Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost (2003) 1.29
Pooling, meta-analysis, and the evaluation of drug safety. Curr Control Trials Cardiovasc Med (2002) 1.29
Early proximal migration of cups is associated with late revision in THA: a systematic review and meta-analysis of 26 RSA studies and 49 survivalstudies. Acta Orthop (2012) 1.28
Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol (2009) 1.28
Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril (2002) 1.26
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood (2002) 1.23
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost (2013) 1.21
Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev (2009) 1.19
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost (2005) 1.19
Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica (2002) 1.16
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol (2007) 1.15
Upper extremity deep venous thrombosis. Semin Thromb Hemost (2006) 1.14
Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol (2012) 1.14
Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost (2010) 1.11
Superficial vein thrombosis: risk factors, diagnosis, and treatment. Semin Thromb Hemost (2006) 1.11
Sex and anticoagulation in patients with idiopathic venous thromboembolism. Lancet (2006) 1.11
Simplification of the diagnostic management of suspected deep vein thrombosis. Arch Intern Med (2002) 1.09
Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus. Cardiovasc Diabetol (2009) 1.09
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis (2003) 1.08
Cystatin C-based equations in renal transplantation: moving toward a better glomerular filtration rate prediction? Transplantation (2008) 1.06
A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril (2006) 1.06
Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res (2004) 1.05
Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. Europace (2013) 1.05
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev (2011) 1.04
The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. Eur J Epidemiol (2013) 1.03
Involvement of microparticles in diabetic vascular complications. Thromb Haemost (2011) 1.02
Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood (2002) 1.02
Preventing venous thromboembolism in medical patients. Circulation (2004) 1.01
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica (2003) 1.00
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost (2004) 0.99
New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear. J Clin Epidemiol (2007) 0.98
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica (2007) 0.98
Prevalence of upper extremity deep venous thrombosis diagnosed by color Doppler duplex sonography in cancer patients with central venous catheters. J Ultrasound Med (2006) 0.98